The PVRI is registered as a charity in the UK and as a not-for-profit organisation in the USA. It is governed by a group of trustees who form the Council of the PVRI. The PVRI’s constitution can be viewed by clicking the button below.
Council of the PVRI
Paul Corris (President)
Paul Corris MD is Professor of Thoracic Medicine and is a tenured faculty member of the Institute of Cellular Medicine at Newcastle University. He is an honorary consultant physician at The Newcastle Hospitals NHS Foundation Trust Newcastle upon Tyne, UK, and directs the National Pulmonary Vascular Service (Newcastle). He is Deputy Director of the Transplant Institute within the Institute of Cellular Medicine at Newcastle University and is Past-President of both the British Thoracic Society and the International Society for Heart and Lung Transplantation. In 2014, he was elected President Elect of the international Pulmonary Vascular Research Institute (PVRI) and is currently chairman of the NHS England Clinical Reference Group for Pulmonary Hypertension. Professor Corris played significant roles in establishing lung transplantation as a viable clinical therapy for patients with end stage lung disease internationally, and in setting up the UK National Pulmonary Hypertension Service Collaborative. He currently sits on the editorial boards of Pulmonary Circulation, Frontiers in Pulmonary Medicine and the Journal of Heart and Lung Transplantation. Previously, he was Associate Editor of Thorax and is the author of 275 peer reviewed manuscripts and 40 book Chapters. He has been a faculty member and author of guidelines within his specialty interests of lung transplantation and pulmonary hypertension for many societies and world groups. His research has been highly cited and is focused on translational and clinical science relating to both lung transplantation and pulmonary hypertension. His interests outside medical science include wine, music, mountains and sport, particularly rugby and soccer.
Stephanie Barwick (Chief Executive)
Stephanie is a German national who came to the UK in 1993 after graduating with a ‘First’ degree in European Business Studies with French & English Language from the University of Munich.
She is currently the CEO of the Pulmonary Vascular Research Institute, a position she started in 2014, as the Charity’s first full-time employed Chief Executive.
Stephanie is based in the PVRI UK central office in Canterbury and her role is to manage and oversee all aspects of the Institute including the day-to-day operations, managing all the Charity’s international bank accounts, liaising with donors and sponsors on annual donations as well as implementing the strategic vision set by the PVRI Board of Directors.
Prior to her role at the PVRI, Stephanie has held various positions within the private and public sectors, including her most recent role as ‘Senior Enterprise Manager’ at the University of Kent where she was in charge of the University’s business start-up unit, supporting students, graduates and staff to set up successful companies. During her time there, she invented and developed the pioneering Employability Points Scheme, an industry-university based collaboration which recognises the demands of employers as well as the challenges graduates face when seeking employment. After only two years, she scheme involved over 3,000 students and 120 employers. In 2012 it was nominated for a Times Higher University Education Award and was showcased by the UK government department BIS (Business Innovation Skills) as a best practice model for a university-industry collaboration. For her innovative work, Stephanie was awarded the prestigious ‘Barbara Morris’ prize in 2011 by the University of Kent in recognition of her achievements.
Stephanie is a qualified Business Counsellor and has been involved in lecturing one of the Kent Business School’s entrepreneurship modules for undergraduate students from all disciplines who are interested in business start-up. She has extensive knowledge in working with large corporate businesses across the globe as well as small companies, who emerge from a university setting.
Sheila G. Haworth (Past President)
Professor Haworth Professor Emeritus, University College, London, trained in neonatal medicine and paediatric cardiology and then specialised in pulmonary hypertension.
She became Professor of Developmental Cardiology at Great Ormond Street Hospital for Children and had a British Heart Foundation (BHF) Professorial Chair and research group. Her basic science focused on the pathobiology of paediatric pulmonary hypertension and adaptation of the pulmonary circulation to extra-uterine life. Professor Haworth was Head of Cardiorespiratory Sciences at the Institute of Child Health, University College London.
In 2002, she founded the UK Pulmonary Hypertension Service for Children - a comprehensive clinical network caring for all children in the UK with significant pulmonary hypertension. She has published extensively and helped train pulmonary hypertension specialists, who are now leaders in the field. Professor Haworth has served on the BHF Executive Committee and the BHF Research Funds Committee, working groups of the Royal Colleges; Selection Committee of the Academy of Medical Sciences, London; and became a fellow of the American College of Cardiology and a member of the Cardio-Pulmonary Committee of the American Heart Association.
Martin Wilkins (Treasurer)
Martin R Wilkins MD FRCP FBPhS FMedSci is Head of Department of Medicine, Imperial College, London, and is a physician-scientist with a background in clinical pharmacology and toxicology.
He has spent the past 25 years investigating the molecular pathology of pulmonary hypertension with a view to identifying novel drug targets and better ways of monitoring the disease.
He has published widely on the cyclic GMP signalling pathway and circulating biomarkers. More recently he has investigated the role of iron homeostasis and zinc transport in pulmonary vascular disease.
His research is supported by the British Heart Foundation, Medical Research Council, the Wellcome Trust and the National Institute of Health Research.
Nick Morrell (Editor of Pulmonary Circulation)
Nick Morrell MD FRCP FMedSci qualified in Medicine (MB BS) from Charing Cross and Westminster Medical School (now Imperial College, London) in 1987. He undertook his research MD at Charing Cross Hospital and then spent two years in Denver, Colorado, as a British Heart Foundation fellow before returning as a Lecturer to complete training in General and Respiratory Medicine at the Royal Postgraduate Medical School, Hammersmith Hospital (now part of Imperial College School of Medicine). He was appointed Senior Lecturer and Honorary Consultant at Hammersmith Hospital, Imperial College in 1998 and was awarded an MRC Clinician Scientist Fellowship. He moved to the University of Cambridge in 2000 as University Lecturer and Honorary Consultant at Addenbrooke’s and Papworth Hospitals, and was appointed Professor of Cardiopulmonary Medicine in 2007. In 2009, he was awarded a British Heart Foundation Professorship and in 2011 elected to the fellowship of the Academy of Medical Sciences of the UK. He has chaired the programme committees for the British and American Thoracic Societies. He is a member of the MRC Clinical Fellowships Committee, Director of the BHF Cambridge Centre for Cardiovascular Research Excellence and leads the Cardiovascular Theme of the NIHR Cambridge Biomedical Research Centre. He is Research Director of the National Pulmonary Vascular Diseases Unit at Papworth Hospital and a National Institute of Health Research Senior Investigator. His research focuses on understanding genetic causes of cardiovascular disease, particularly pulmonary arterial hypertension, and developing new treatments for these conditions. He has published over 200 papers in this field. More recently he has been involved in exciting new genomics initiatives in the UK to apply whole genome sequencing to understanding the genetic basis of rare diseases, including pulmonary arterial hypertension, and to apply this technology to the direct care of patients.
Paul Hassoun (President Elect)
Dr Paul M. Hassoun is a professor of medicine at the Johns Hopkins University School of Medicine. His areas of clinical expertise include pulmonary disease and critical care medicine.
Dr Hassoun serves as the director of the Pulmonary Hypertension Program.
He earned his MD from Faculte de Medecine Lariboisiere. He completed his residency at Brigham and Women's Hospital and performed a fellowship at Massachusetts General Hospital and at New England Medical Center Hospitals.
Dr Hassoun's research interests include acute lung injury, regulation and role of xanthine oxidase in lung injury, and molecular determinants of pulmonary hypertension.
He was recognised by the Department of Medicine with a Levine Excellence in Mentoring Award in 2008. He is a member of numerous professional organisations, including the American Heart Association, the American Thoracic Society and the European Respiratory Society.
Dr Stuart Rich MD is a cardiologist and Director of Northwestern Medicine’s Pulmonary Vascular Disease Programme at the Bluhm Cardiovascular Institute and a Professor of Medicine, Northwestern University Feinberg School of Medicine.
He is one of the world’s most recognised experts on pulmonary vascular diseases. For more than three decades he has dedicated his research and clinical efforts to finding better solutions for pulmonary hypertension.
Dr Rich completed his residency training in medicine at Washington University in St Louis, and fellowship in cardiology at the University of Chicago. His career began at the University of Illinois, where he was principal investigator for the National Institutes of Health (NIH) Registry on Primary Pulmonary Hypertension, the first of its kind, and has been the leader of the largest clinical centre in the US for evaluating and treating patients with pulmonary hypertension since 1980. Dr Rich has conducted cutting-edge research on the molecular mechanisms, epidemiology, clinical presentation, natural history and treatments of the disease and been at the forefront of the development of virtually every new treatment for pulmonary hypertension, as well as the use of therapeutic procedures and devices. His pioneering research has led to a greater understanding of all types of pulmonary hypertension.
Sir Magdi Yacoub FRS is Executive Director of the Qatar Cardiovascular Research Centre in collaboration with the Qatar Foundation, Magdi Yacoub Research Network and Hamad Medical Corporation.
He is also Professor of Cardiothoracic Surgery at the National Heart and Lung Institute, Imperial College London and Founder and Director of Research at Harefield Heart Science Centre (Magdi Yacoub Institute) overseeing 60 scientists and students focused on tissue engineering, myocardial regeneration, stem cell biology, end stage heart failure and transplant immunology.
Professor Yacoub established the largest heart and lung transplantation programme in the world where more than 2,500 transplant operations have been performed. He has also developed novel operations for a number of complex congenital heart anomalies as well as leading research including tissue engineering heart valves, myocardial regeneration, novel left ventricular assist devices and wireless sensors with collaborations within Imperial College, nationally and internationally.
Sir Magdi has an active interest in global healthcare delivery with focus on developing programmes in Egypt, The Gulf Region, Mozambique, Ethiopia and Jamaica.
He is Founder and President of the Chain of Hope charity, treating children with correctable cardiac conditions from developing countries and establishing training and research programmes in local cardiac units.
Bert van den Bergh
Bert van den Bergh is President of Revalesio Corporation where he leads the development and commercialisation of the company’s RNS60 therapeutic.
Bert has a proven track record of successfully commercialising novel medicines and has led business operations at major pharmaceutical companies around the world.
Bert started his career at Eli Lilly & Company, working his way up to multiple senior executive positions across the company’s US and European operations. He most notably served as President of Neuroscience Products, President of European Operations and General Manager for the UK and Germany. In these roles, Bert was instrumental in the development, commercialiSation and lifecycle management of innovative pharmaceuticals like Cymbalta, Prozac, Strattera and Zyprexa.
Most recently, Bert served as Chairman of the Board at Correvio, LLC. In addition to his role at Revalesio, Bert serves on a variety of nonprofit boards and advisory committees, including the Pulmonary Vascular Research Institute, Mental Health America and Peers for Progress. He holds a bachelor’s degree in business administration from Nijenrode Business School (The Netherlands) and an MBA from Interfaculty Delft/Rotterdam, now the Rotterdam School of Management (The Netherlands).
Dr Declan Doogan, MD, serves as an Executive Chairman of Biohaven Pharmaceuticals. Dr Doogan has been the Chief Executive Officer of Portage Biotech Inc. since June 4, 2013. He is a co-founder and serves as Managing Partner of Topix. Dr Doogan is a Venture Partner of Fidelity Biosciences and joined it in October 2007. Dr Doogan served as the Chief Medical Officer of Amarin Corporation Plc since August 2010. He served as the Chief Executive Officer of Bontan Corporation, Inc. since June 2013. Dr Doogan served as an Executive Director of Amarin Corp. Plc from December 2007 to May 2008.
He is in pharmaceutical research and development for most of his professional life, starting first in the Netherlands as a Project Physician. Dr Doogan has more than 30 years' experience of the global pharmaceuticals industry, including more than 20 years with Pfizer. He joined Amarin Corp. Plc in 2007 as Head of Research and Development. He served as Chief Medical Officer and Executive Vice President at Prometheus Laboratories Inc. since September 2010.
Dr Doogan joined Pfizer in 1982, where he was in charge of the sertraline(R) (Zoloft) clinical development programme. He has held a number of senior positions in research and development in Pfizer in the United States, United Kingdom, and Japan, where he served as Medical Director and Head of its development organisation. Dr Doogan served at Pfizer Global Research & Development until April 2007, where he served as the Senior Vice President and Head of World Development. He served as the President of Research & Development of Amarin Corp. Plc since April 10, 2007 and Interim Chief Executive Officer from 2009 to 2010. He served as Non-Executive Chairman of Spinifex Pharmaceuticals Pty Limited since December 2011 and serves as its Member of Scientific Advisory Board. He serves as the Chairman of Portage Biotech Inc. Dr Doogan holds a number of Non-Executive directorships, including Board Member of Alimentary Health Limited, and Odyssey UK. He serves as a Member of the Advisory Board at Urban Interactions, Inc.
He serves as a Director of Heptares Therapeutics Ltd. He has been a Director of Portage Biotech Inc. since June 4, 2013. He serves as a Non Executive Director of Trojantec Ltd. He serves as a Director of Trojan Technologies USA, LLC. He has been an External Director of Sosei Group Corporation since June 2007. He served as a Director of Bontan Corporation, Inc. since June 2013. He serves as a Director of Sosei Co. Ltd. He serves as a Director of Spinifex Pharmaceuticals Inc. and has been its Member of Scientific Advisory Board since May 2014. He served as a Director of Spinifex Pharmaceuticals Pty Limited since December 2011. He holds a number of Board appointments principally in pharmaceutical research and development. Dr Doogan is also involved in charities such as the Haitian Health Foundation, the Pulmonary Vascular Research Institute, and Odessey. He is Visiting Professor at Harvard School of Public Health, Glasgow University Medical School, and Kitasato University (Tokyo). He is Adjunct Professor of Psychiatry at the University of Cork. Dr Doogan is interested not only in the scientific aspects of drug development but also in defining new strategies to improve yield and effectiveness in human drug development. He is a Fellow of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine in the United Kingdom. Dr Doogan received his Medical degree from Glasgow University in 1975. He received a Doctorate of Science from the University of Kent, UK. He graduated in Physiology and Zoology from The University of Sheffield.
Ahvie Herskowitz, MD co-founded The Institute for OneWorld Health in 2000 and served as its Chief Medical Officer. Dr Herskowitz has extensive experience performing large-scale multinational phase II and III clinical trials. Prior to co-founding iOWH, he directed all multinational clinical trials at a cardiovascular research institute, including all epidemiologic and outcome studies and registries. He serves as Director of The Institute for OneWorld Health. Dr Herskowitz has been trained in the fields of cardiology, immunology and pathology. A former Associate Professor of Medicine, Immunology and Molecular Microbiology at Johns Hopkins, Dr Herskowitz is a Clinical Professor in the Department of Medicine at University of California, San Francisco. He received his MD from Albert Einstein College of Medicine.
Hossein Ardeschir Ghofrani MD is Professor of Pulmonary Vascular Research at Justus Liebig University, Giessen, Germany and Head of the Pulmonary Hypertension Division at the University Hospital in Giessen.
In addition, he is Director of Pneumology as well as Medical Executive Director at the Kerckhoff Clinic in Bad Nauheim, Germany and part-time Professor for Pulmonary Vascular Medicine at Imperial College London.
He leads a translational research group on development of new therapeutics for Cardiopulmonary Vascular disease and is member of the steering committee of the Excellence Cluster Cardio-Pulmonary System (www.eccps.de) and founding member of the Pulmonary Vascular Research Institute. He has participated in the development of several therapeutics for chronic lung diseases and pulmonary hypertension, including prostanoids, phosphodiesterase inhibitors, endothelin receptor antagonists, tyrosine kinase inhibitors and stimulators of the soluble guanylate cyclase.
Professor Ghofrani has received four awards for investigations in pulmonary vascular science, is a fellow of the European Respiratory Society (FERS) and reviewer for several medical scientific journals.
Antonio Augusto Lopes
He is fellow of the Pulmonary Vascular Research Institute and member of the Paediatric and Congenital Heart Disease Task Force. He is also Associate Editor of Pulmonary Circulation. In addition, fellow of the American Heart Association, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation and International Adviser to the Saudi Association for Pulmonary Hypertension - Paediatric and Congenital Heart Disease Task Force.
Investigations and publications related to pulmonary vascular disease in the paediatric population and associated with congenital heart disease (children and adults).
His particular interest is in microvascular dysfunction markers (endothelial and platelet markers) and mediators of inflammation in pulmonary arterial hypertension (paediatric and adult).
His research work focuses mainly on translational medicine.